Akamis Bio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Akamis Bio sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Akamis Bio: 6 sponsored US clinical trials, 1 recruiting.
Akamis Bio sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epithelial Tumor, with 2 trials.
Upper-quartile sponsor footprint
Akamis Bio sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
NCT05165433
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
NCT05043714
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
NCT04053283
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
NCT03852511
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
NCT02636036
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
What is open in the Akamis Bio pipeline
1 recruiting of 6 indexed (17% open); 5 completed (83%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Epithelial Tumor (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Akamis Bio: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Akamis Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
- Anthos Therapeutics · 17% recruiting · 6 trials
Related
What to do with this Akamis Bio page
6 registered trials is a research-attention snapshot, not an endorsement of Akamis Bio or any single study.
- 1 of Akamis Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Epithelial Tumor is the condition Akamis Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epithelial Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Akamis Bio pipeline card: 6 registered trials from official public datasets.Report a data error.